It was decision day for the best U.S. women’s hockey players, and Rory Guilday was cautiously confident despite being cut ...
The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results